Investigating the link between ADHD and basal ganglia disorders
Psychostimulants, Attention Deficit and Basal Ganglia Disorders
This study looks at how having ADHD might be linked to brain disorders like Parkinson's disease and whether medications that help with ADHD, like amphetamines and methylphenidate, could affect the chances of developing these conditions, so we can better understand the long-term impact of these treatments on brain health.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10692609 on NIH RePORTER |
What this research studies
This research explores the relationship between attention-deficit/hyperactivity disorder (ADHD) and disorders affecting the basal ganglia, such as Parkinson's disease. It examines how the use of dopaminergic psychostimulants, like amphetamine and methylphenidate, may influence the risk of developing these disorders in individuals with ADHD. The study involves analyzing data from individuals with ADHD to assess their risk of developing basal ganglia disorders compared to those without ADHD. By understanding these connections, the research aims to provide insights into the long-term effects of stimulant treatment on brain health.
Who could benefit from this research
Good fit: Ideal candidates for this research include adolescents and young adults diagnosed with ADHD who are currently receiving or have received treatment with psychostimulants.
Not a fit: Patients without a diagnosis of ADHD or those who have not been treated with psychostimulants may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for ADHD that minimize the risk of developing serious neurological disorders later in life.
How similar studies have performed: Previous research has indicated a connection between ADHD and an increased risk of basal ganglia disorders, suggesting that this study builds on established findings rather than exploring a completely novel area.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Fleckenstein, Annette — University of Utah
- Study coordinator: Fleckenstein, Annette
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.